Back to search results

Observational Study on Immunotherapy and Heart Health

This study is looking at how immune checkpoint inhibitors (a type of cancer therapy) affect both cancer and heart health. Researchers want to understand why some people develop heart problems (cardiotoxicity) while on this treatment, and how that relates to their cancer response. They will be looking at traditional heart disease risk factors, as well as new measures like metabolomic profiles (chemical fingerprints of body processes), epigenetic aging (how old your cells appear), and CHIP (a genetic change). You can join if you are 18 or older and are planning to start immune checkpoint inhibitor therapy for cancer. The study aims to identify factors that predict heart problems or cancer progression/death, and to separate what predicts heart problems from what predicts successful cancer treatment. The current recruitment status is unclear.

Study design
This is an observational study, meaning researchers will be watching and collecting information without giving any specific treatments. It plans to include about 1200 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety and side effects will be measured throughout the study, for an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07382752

Decoupling Immunotherapy Toxicity and Cancer Response

Recruiting
Not specifiedAges 18+Observational
M.D. Anderson Cancer Center
~1,200 participants
Updated 2026-07-16 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Adverse Events (AEs)
Measured over Through study completion; an average of 1 year

Conditions

Tumor
Cardiovascular

Explore related trials

Solid Neoplasm

NCT07382752

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • The University of Texas M. D. Anderson Cancer Center

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Nicolas Palaskas, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Nicolas Palaskas, MD
[email protected]
832-750-1109
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Safety and Adverse Events (AEs)Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0